Key Insights by Martin Zapata Laguado from ASCO25

At ASCO 2025, Dr. Martin Zapata Laguado shared key insights across multiple pivotal studies shaping the future of oncology. From groundbreaking trials in glioma and renal cell carcinoma to major developments in bladder cancer treatment, his curated highlights reflect the evolving landscape of personalized care, immunotherapy combinations, and long-term outcomes.

Some of the ASCO 2025 Highlights Shared by Martin Zapata Laguado:

CATNON Trial Final Results

Final results in CATNON trial presented by MartinvdenBent genomic profile have prognosis value, not predictive, Concurrent TMZ and RTand adjuvant TMZ vs RT and adjuvant TMZ not impact onOS Lack data on grade 4.

Pemigatinib in GBM and High-Grade Glioma

Pemigatinib in GBM and high grade glioma negative study, more data in mgmt positive and FGFR mutated patients is needed, however better results in those inhibitors.

KEYNOTE-564 (KN564) Update

Update data on KN564 maintain benefit on OS, all patients in the trial benefit from Pembro adjuvant, however we lack more biomarkers perhaps a measure in KIM1 would be outstanding.

PDIGREE Trial in RCC

PDIGREE trial very interesting adaptative trial, shows step1 with very promising data with fewer patients with poor risk and bone metastasis.

SURE Trial in Muscle-Invasive Bladder Cancer (MIBC)

SURE trial interesting phase 2 trial of the combination of sacituzumab govitecan plus Pembro in MIBc, shows a very interesting CR rate of 44% and luminal like fenotype could benefit of IO more.

CheckMate-901 (CM901) in mUC

CM901 in mUC, shows the arm of IO IO in inelegible cisplatin patients and the combo doesn’t improve OS compared to carbo gem, however interesting data on the responders.

JAVELIN Bladder Medley Trial

JAVELIN bladder medley phase 2 trial using avelumab and sacituzumab vs avelumab shows a very interesting positive PFS results in mUC, OS is not yet accomplished and suggest a rol of combo antitrop2.

EV-302 Data in mUC

EV302 Data on responders in those patients with mUC, can we talk about cure? Impressive data on responders, long survivors, appropriate dose reductions must be done to improve QOL and reduce toxicity.

Discussion on mUC and Anti-TROP2 Therapy

Great discussion on mUC highlighting the posible role on anti trop2 therapy, EV302 maintains the SOC in MUC.

NIAGARA Trial and ctDNA in miUC

NIAGARA analysis in miUC using ctDNA, shows a promising opportunity as a predictive tool, showing once again a strong prognosis tool, we need to include these tools to personalise treatment.

CheckMate-214 (CM214) Long-Term Data in mRCC

CM214 mRCC patients keeps showing amazing results after 9 year of treatment, nearly 30% maintains the benefit, long survivors.

New Combinations in mRCC: Belzutifan + TKI

New players in the management of mRCC patients with casdatifan plus a great TKI, shows similar data on toxicity compared to others antihif therapies.

Dr. Zapata Laguado’s ASCO 2025 highlights showcase a year of both validation and innovation—where long-term survivorship data, adaptive trial designs, and molecular profiling converge to redefine standards of care. As the oncology community moves forward, these insights underscore the critical need for biomarker-driven approaches and thoughtful integration of novel therapies to optimize patient outcomes.

Stay Informed

If you found these highlights valuable, don’t forget to follow OncoDaily for more expert insights, clinical updates, and frontline perspectives from the world of oncology. There’s always more to learn—and we’re here to keep you connected.